Kroger says press release announcing acceptance of bitcoin cash is fake
Nov 5 (Reuters) – A spokesperson of Kroger Co said on Friday a press release saying the grocer would accept “bitcoin cash” this holiday season was fraudulent.
The release appeared on Kroger’s investor relations page. It was not immediately clear how the release made it to the company’s website.
Park Avenue West closed early Friday after triple shooting
An early morning shooting near Coors Field on Friday has sent three men to the hospital, according to the Denver Police Department.
The triple shooting has forced police to close an essential part of Park Avenue West from Interstate 25 to Larimer Street. The closure was originally for inbound and outbound Park Avenue West but is now only for those heading towards the highway. Officials are advising that drivers avoid the area.
All three men have serious injuries, police said.
Police first reported the incident just after 4:15 a.m. on Friday at Park Ave West and Globeville Road.
Pre-market Movers: RWLK, OTRK, EVAX, NRXP, PTON…
The following are some of the stocks making big moves in Friday’s pre-market trading (as of 05.30 A.M. EDT).
In the Green
ReWalk Robotics Ltd. (RWLK) is up over 70% at $2.20
Ontrak, Inc. (OTRK) is up over 37% at $13.30
Assertio Holdings, Inc. (ASRT) is up over 30% at $1.45
JFrog Ltd. (FROG) is up over 13% at $40.30
Borr Drilling Limited (BORR) is up over 12% at $1.18
Expedia Group, Inc. (EXPE) is up over 11% at $175.88
Puxin Limited (NEW) is up over 11% at $0.69
Funko, Inc. (FNKO) is up over 9% at $19.05
Insignia Systems, Inc. (ISIG) is up over 8% at $8.02
Endo International plc (ENDP) is up over 8% at $5.35
RISE Education Cayman Ltd (REDU) is up over 6% at $0.79
Baosheng Media Group Holdings Limited (BAOS) is up over 5% at $1.77
In the Red
Evaxion Biotech A/S (EVAX) is down over 37% at $7.89
NRx Pharmaceuticals, Inc. (NRXP) is down over 35% at $5.73
Peloton Interactive, Inc. (PTON) is down over 32% at $58.25
bluebird bio, Inc. (BLUE) is down over 28% at $18
Puma Biotechnology, Inc. (PBYI) is down over 19% at $5.15
TDH Holdings, Inc. (PETZ) is down over 15% at $3.62
Chembio Diagnostics, Inc. (CEMI) is down over 11% at $2.17
Aditxt, Inc. (ADTX) is down over 10% at $2.25
Dynavax Technologies Corporation (DVAX) is down over 9% at $18.89
Redbox Entertainment Inc. (RDBX) is down over 9% at $16.30
FAT Brands Inc. (FATBB) is down over 6% at $15.48
FDA authorizes Pfizer's Covid-19 vaccine for children 5 to 11
New York (CNN Business)Shares of drug giant Pfizer surged more than 10% in early trading Friday after the company announced positive test results for an experimental pill it has developed to fight Covid-19.
Pfizer (PFE) said the pill reduced the risk of hospitalization and death for high-risk patients who were part of a trial taking the drug.
The news comes just a few days after Pfizer reported strong earnings and sales, thanks largely to the success of the Covid-19 vaccine it developed with BioNTech (BNTX).
The US Food and Drug Administration also recently approved the use of the Pfizer-BioNTech vaccine in 5- to 11-year-old children.
But shares of BioNTech, which will report earnings next week, plunged in early trading Friday. So did shares of Pfizer’s Big Pharma rival Merck (MRK), which also is developing a Covid pill.
Moderna (MRNA), another biotech that has its own Covid-19 vaccine, fell more than 10% in early trading Friday.
That follows a nearly 18% slide for the stock Thursday after Moderna announced weaker than expected results and a disappointing outlook due to production and shipment problems that will delay the deliveries of its vaccine.
Pfizer’s COVID-19 Antiviral Candidate Shows Potential To Reduce Risk Of Hospitalization By 89%
Pfizer Inc. (PFE) said its investigational COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization and death, based on an interim analysis of the phase 2/3 EPIC-HR double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. In the study, PAXLOVID was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19, the company said.
Pfizer noted that, in the overall study population through day 28, no deaths were reported in patients who received PAXLOVID as compared to 10 deaths in patients who received placebo.
“These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” said Albert Bourla, CEO, Pfizer.
Pfizer plans to submit the data as part of its ongoing rolling submission to the FDA for Emergency Use Authorization as soon as possible.
Shares of Pfizer Inc. were up 10% in pre-market trade on Friday.
Goodyear Tire & Rubber Q3 Profit Beats Estimates; Sales Up 42% – Quick Facts
The Goodyear Tire & Rubber Company (GT) reported an increase in profit for the third quarter that also topped Wall Street estimates. Sales were up 42% from a year ago, driven by the Cooper Tire merger, improvements in price/mix, increased sales from other tire-related businesses and higher volume.
Third quarter adjusted net income per share was $0.72 compared to $0.10, last year. On average, eight analysts polled by Thomson Reuters expected the company to report profit per share of $0.29, for the quarter. Analysts’ estimates typically exclude special items. Net income was $132 million or $0.46 per share compared to a net loss of $2 million or $0.01 per share.
Sales were $4.9 billion, up 42% from a year ago. Analysts on average had estimated $4.75 billion in revenue. Excluding the Cooper Tire transaction, growth was 16%. Tire unit volumes were 48.2 million, up 32% from last year.
Shares of Goodyear Tire & Rubber Company were up 12% in pre-market trade on Friday.